Granules India Limited (BOM:532482)
491.95
+24.60 (5.26%)
At close: Aug 29, 2025
Granules India Revenue
Granules India had revenue of 12.10B INR in the quarter ending June 30, 2025, with 2.56% growth. This brings the company's revenue in the last twelve months to 45.12B, down -4.02% year-over-year. In the fiscal year ending March 31, 2025, Granules India had annual revenue of 44.82B, down -0.55%.
Revenue (ttm)
45.12B
Revenue Growth
-4.02%
P/S Ratio
2.65
Revenue / Employee
11.10M
Employees
4,066
Market Cap
119.37B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 44.82B | -247.59M | -0.55% |
Mar 31, 2024 | 45.06B | -55.50M | -0.12% |
Mar 31, 2023 | 45.12B | 7.47B | 19.84% |
Mar 31, 2022 | 37.65B | 5.27B | 16.29% |
Mar 31, 2021 | 32.38B | 6.39B | 24.59% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,765.41B |
HDFC Bank | 2,736.06B |
Bharti Airtel | 1,839.41B |
Tata Consultancy Services | 2,561.48B |
ICICI Bank | 2,054.85B |
State Bank of India | 3,503.84B |
Infosys | 1,672.76B |
Hindustan Unilever | 639.28B |
Granules India News
- 17 days ago - Granules India Q1 Results: Revenue jumps 2.56% YoY to Rs 1,210.11 crore, net profit falls 16.37% YoY - Business Upturn
- 4 weeks ago - Granules India’s Hyderabad unit receives one US FDA observation after Pre-Approval Inspection - Business Upturn
- 6 weeks ago - Granules India CEO Kandiraju Venkata Sitaram Rao resigns, effective July 31 - Business Upturn
- 2 months ago - Granules India clears US FDA Pre-Approval Inspection with zero observations - Business Upturn
- 2 months ago - Granules India’s Bonthapally facility completes US FDA inspection with one observation - Business Upturn
- 2 months ago - Pharma scrips fall on Trump tariff threat - The Times of India
- 6 months ago - Granules India shares drop nearly 3% amid US FDA warning letter - Business Upturn
- 6 months ago - Granules India shares drop 3.6% after receiving US FDA warning letter for Gagillapur facility - Business Upturn